Cargando…

Albuminuria as a marker of systemic congestion in patients with heart failure

AIMS: Albuminuria is common in patients with heart failure and associated with worse outcomes. The underlying pathophysiological mechanism of albuminuria in heart failure is still incompletely understood. The association of clinical characteristics and biomarker profile with albuminuria in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boorsma, Eva M, ter Maaten, Jozine M, Damman, Kevin, van Essen, Bart J, Zannad, Faiez, van Veldhuisen, Dirk J, Samani, Nilesh J, Dickstein, Kenneth, Metra, Marco, Filippatos, Gerasimos, Lang, Chim C, Ng, Leong, Anker, Stefan D, Cleland, John G, Pellicori, Pierpaolo, Gansevoort, Ron T, Heerspink, Hiddo J L, Voors, Adriaan A, Emmens, Johanna E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890244/ https://www.ncbi.nlm.nih.gov/pubmed/36148485 http://dx.doi.org/10.1093/eurheartj/ehac528

Ejemplares similares

The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
por: Pandhi, Paloma, et al.
Publicado: (2021)

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
por: Inciardi, Riccardo M., et al.
Publicado: (2022)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2020)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2021)

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
por: Sama, Iziah E, et al.
Publicado: (2020)

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2019)

Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2020)

Pathophysiological pathways in patients with heart failure and atrial fibrillation( )
por: Santema, Bernadet T, et al.
Publicado: (2021)

Impaired High‐Density Lipoprotein Function in Patients With Heart Failure
por: Emmens, Johanna E., et al.
Publicado: (2021)

Clinical implications of low estimated protein intake in patients with heart failure
por: Streng, Koen W., et al.
Publicado: (2022)

Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence
por: Bracun, Valentina, et al.
Publicado: (2022)

A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure
por: Sama, Iziah E., et al.
Publicado: (2020)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
por: Nauta, Jan F., et al.
Publicado: (2019)

Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire
por: Ravera, Alice, et al.
Publicado: (2021)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
por: Markousis-Mavrogenis, George, et al.
Publicado: (2021)

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure
por: Cao, Thong Huy, et al.
Publicado: (2018)

Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
por: Cao, Thong H., et al.
Publicado: (2019)

Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction
por: Curran, Fraser M., et al.
Publicado: (2021)

Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure
por: de Koning, Marie-Sophie L. Y., et al.
Publicado: (2023)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure
por: Al-Mubarak, Ali A., et al.
Publicado: (2020)

Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure
por: Nath, Mintu, et al.
Publicado: (2022)

Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
por: Emmens, Johanna E., et al.
Publicado: (2021)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes
por: Hellemons, Merel E., et al.
Publicado: (2012)

Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) trial
por: ter Maaten, Jozine M., et al.
Publicado: (2022)

Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure
por: Markousis-Mavrogenis, George, et al.
Publicado: (2023)

Longitudinal relationship between albuminuria in infancy and childhood
por: Gracchi, Valentina, et al.
Publicado: (2023)

Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial
por: ter Maaten, Jozine M., et al.
Publicado: (2023)

How to measure and monitor albuminuria in healthy toddlers?
por: van den Belt, Sophie Marielle, et al.
Publicado: (2018)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i2t08s7qnohupsderm9r5s2t31